Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05881239 · ClinicalTrials.gov registry record
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
A clinical trial of Mild Cognitive Impairment and Healthy Aging, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT05881239 is a study of Mild Cognitive Impairment and Healthy Aging that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 250 participants, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05881239, a study of Mild Cognitive Impairment and Healthy Aging, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched controls. The main question it aims to answer is whether the AROMHA Brain Health Test could serve as a predictive biomarker of neurodegenerative disorders. This understanding will aid in the development of a noninvasive, cost-effective diagnostic tool that reliably and specifically distinguishes disease and normal aging populations. Participants will take the approximately 45-minute AROMHA Brain Health Smell Test where they will peel and sniff labels on the physical smell cards and answer questions on the web-based app relating to what they smelled. Participants will undergo tests for odor intensity, odor identification, odor discrimination, and episodic olfactory memory, but will not be provided the results of these tests.
Conditions Studied
Interventions
- DEVICE AROMHA Brain Health Test
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-05-09 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05881239
The ClinicalTrials.gov registry entry for NCT05881239 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (80% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which AROMHA Brain Health Test is the first listed.
NCT05881239 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05881239 about?
NCT05881239 is a clinical study titled "Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD". The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched controls. The main question it aims to answer is whether the AROMHA Brain Healt...
What is the current status of trial NCT05881239?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2023-05-09. Estimated completion is 2027-12-31.
What conditions does trial NCT05881239 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Healthy Aging, Subjective Cognitive Concerns, Mild Behavioral Impairment.
What interventions are being tested in trial NCT05881239?
The interventions under investigation include: AROMHA Brain Health Test (DEVICE).
Who is sponsoring clinical trial NCT05881239?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05881239 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.